Recently, T cells engineered to express an exogenous T cell receptor targeting tumor antigens via delivery of Cas9–RNP and DNA templates have been shown to mount effective anti-tumor responses in vitro, in murine models15,16, and in early stage clinical trials5. Here, RNPC3 is linked to neoplasm.